---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007060"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:33:31.709268+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma Q1 operating loss $10.2M; secures $35M loan at 14% from Innoviva

## Summary
- Grant revenue $1.0M (up from $0.8M YoY); R&D expense $8.0M (down from $9.6M); G&A $3.2M (up from $2.5M).
- Cash $37.9M as of March 31, 2024 vs $13.5M at Dec 31, 2023, aided by $35M credit agreement with Innoviva arm.
- Loan bears 14% annual interest, matures June 4, 2025; principal and interest payable at maturity.
- Phase 2a diSArm (AP-SA02) and Phase 2 Tail wind (AP-PA02) advancing; enrollment on track.
- cGMP manufacturing build-out expected mid-2024; R&D labs and admin space already operational.

## SEC filing metadata
- accession: 0001558370-24-007060
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837024007060/0001558370-24-007060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837024007060/armp-20240507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007060
- JSON: https://secwatch.observer/filing/0001558370-24-007060.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007060.txt

## Key facts
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 7, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024, in the press release furnished hereto as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000155837024007060/0001558370-24-007060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.